Aclaris Therapeutics, Inc. — Form 8-K
Filed October 27, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Aclaris announced positive Phase 1b proof-of-concept results for ATI-052 (anti-TSLP/IL-4Rα bispecific) in atopic dermatitis (14 patients, 3:1 randomization) and asthma (16 patients, 3:1 randomization). In severe AD: 58% absolute EASI reduction (ATI-052) vs. 13% (placebo); 78% placebo-adjusted EASI-50; 38% absolute itch improvement. In asthma: 59% FeNO reduction and +350 mL FEV1 improvement at day 15 (in FEV1 ≥80% subgroup). No Grade 3/4 adverse events; no conjunctivitis. Company will prioritize Phase 2b in eosinophilic esophagitis (EoE), initiating early 2027, with potential additional indications announced later.
Why this rating
Phase 1b POC success in two indications with compelling efficacy and safety validates core mechanism. At $149M market cap, clinical validation of lead asset is material. However, small trial sizes (10–12 active per arm), early stage, and EoE pivot (not AD/asthma initially) introduce execution risk.
Price action (we called it positive)
before filing · preread $4.03 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 27, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.